Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
Holders’ participation is capped at $50 million, and Atossa has not yet received a qualifying priority review voucher.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Atossa Therapeutics (Nasdaq: ATOS) will attach one contingent value right to each outstanding common share at the October 19, 2026 close. These CVRs give holders aggregate rights to 25% of net proceeds from the sale or deemed monetization of its first qualifying priority review voucher, capped at $50 million. The voucher must be awarded by December 31, 2036, unless the board extends that date.
Later-issued shares will also carry one CVR until detachment or agreement expiration. Rights transfer only with their shares while attached; the board may detach them. Using a voucher internally or a change of control while holding an unsold voucher triggers deemed monetization. Atossa has received rare pediatric disease designations for (Z)-endoxifen in two conditions, but has submitted no marketing application for either and received no voucher. Payments depend on qualifying events and legal distribution and solvency requirements.
Positive
- Minor point. Forward-looking: it has not happened yet and may not happen.One CVR per share provides participation rights for outstanding shares and later issuances before detachment or agreement expiration.
- Minor point. Forward-looking: it has not happened yet and may not happen.25% of net proceeds from the first qualifying voucher’s sale or deemed monetization is allocated to CVR holders.
- Minor point. Forward-looking: it has not happened yet and may not happen.Internal voucher use or change of control while holding an unsold qualifying voucher also triggers deemed monetization.
- Minor pointFDA Rare Pediatric Disease Designations received for (Z)-endoxifen in Duchenne muscular dystrophy and McCune-Albright syndrome.
Negative
- Minor point$50 million aggregate cap limits total payments to CVR holders.
- Minor pointNo PRV awarded; no (Z)-endoxifen marketing application submitted for Duchenne muscular dystrophy or McCune-Albright syndrome.
- Minor pointDecember 31, 2036 award deadline limits qualifying vouchers unless the board extends it.
- Minor pointNo contractual obligation requires Atossa to conduct studies, pursue approvals or designations, or monetize a voucher.
- Minor pointLegally permitted distributions and solvency requirements condition any CVR payment.
- Minor pointStapled CVRs cannot trade separately unless the board elects to detach them.
Key Figures
- Share of net proceeds
- 25%
- Aggregate CVR-holder participation in proceeds from the first qualifying PRV
- Aggregate payment cap
- $50 million
- Maximum total payments to CVR holders
- CVRs per share
- 1 CVR per share
- Attached to eligible Atossa common stock
- Outside date
- December 31, 2036
- First qualifying PRV must be awarded by this date, subject to possible extension
Historical Context
-
Executed agreement established shareholder participation in potential voucher proceeds, subject to a 25% share and $50 million cap.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
contingent value right financial
priority review voucher regulatory
cusip technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
One CVR will attach to each outstanding share of Atossa common stock as of the close of business on October 19, 2026, and shares and CVRs will transfer together while stapled
Shares issued after October 19, 2026 will also carry one attached CVR, subject to the terms of the CVR Agreement
Under the terms of the Stapled Contingent Value Rights Agreement (the "CVR Agreement") with VStock Transfer, LLC, as rights agent, each share of Atossa common stock outstanding at the close of business on October 19, 2026 will receive, and have attached, one CVR. Each share issued after the record date and before any detachment of the CVRs or expiration of the CVR Agreement will also carry and have attached one CVR.
The CVRs will remain attached, or "stapled," to Atossa common stock unless and until the Board of Directors elects to detach them (for example, to permit CVRs to trade separately). While stapled, each CVR may be transferred only together with its corresponding share of common stock. Accordingly, when a share carrying a CVR is sold or otherwise transferred, the attached CVR will transfer with that share. While attached, the CVRs will not trade separately, have a separate CUSIP or be reported separately on brokerage statements.
The October 19 record date establishes the shares entitled to the initial CVR dividend; it does not detach the CVRs from those shares. Investors who subsequently acquire shares carrying an attached CVR will acquire the CVR together with the common stock.
"Today's record date marks an important step in providing our shareholders with a contractual opportunity to participate in the potential value of Atossa's first qualifying priority review voucher," said Steven C. Quay, M.D., Ph.D., Atossa's Chairman, President and Chief Executive Officer. "Each CVR will be attached to its corresponding share of Atossa common stock and will transfer with that share while stapled. This structure aligns participation in that potential value with ownership of Atossa common stock, while preserving our flexibility to advance our development programs and allocate capital in the interests of the Company and its shareholders."
Atossa has received FDA Rare Pediatric Disease Designation for (Z)-endoxifen for the treatment of Duchenne muscular dystrophy ("DMD") and McCune-Albright syndrome ("MAS"). If the FDA approves a qualifying marketing application for either program, or another qualifying Atossa development program, the Company may be awarded a priority review voucher ("PRV"), subject to applicable statutory and regulatory requirements.
No Atossa product candidate has been approved by the FDA for any indication, Atossa has not submitted a marketing application for (Z)-endoxifen for DMD or MAS, and no PRV has been awarded to the Company. Rare Pediatric Disease Designation does not itself result in the award of a PRV. There can be no assurance that Atossa will receive or monetize a PRV or that any payment will be made under the CVRs.
Key Terms of the Stapled CVRs
- October 19, 2026, record date. One CVR will be issued for each share of Atossa common stock outstanding at the close of business on that date and will attach to that share.
- Attachment to common stock. Each CVR will remain stapled to its corresponding share and transfer only with that share unless the Board elects to detach the CVRs.
- Shares issued after the record date. Each share issued before any detachment or expiration of the CVR Agreement will also carry one CVR which will be stapled and attached to that share.
25% participation;$50 million 25% of net proceeds from the sale or deemed monetization of Atossa's first qualifying PRV, with total payments capped at$50 million - Deemed monetization. If Atossa uses a qualifying PRV for its own application, or a change of control occurs while Atossa holds an unsold qualifying PRV, the event will be treated as a deemed monetization based on fair market value determined by an independent financial advisor, to which CVR holders will be entitled as stated above.
- Outside date. The CVRs apply to the first qualifying PRV awarded to Atossa on or before December 31, 2036, subject to the Board's ability to extend that date under the CVR Agreement.
The CVR Agreement does not require Atossa to conduct any particular clinical study, pursue or obtain any regulatory approval or designation, or sell or otherwise monetize a PRV. Atossa retains discretion over its development, regulatory and commercial strategy, including whether and when to sell, use or retain any PRV it may receive. Any payment remains subject to the CVR Agreement, including its provisions concerning legally permitted distributions and solvency.
The CVR Agreement was filed with the
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company's lead product candidate, (Z)-endoxifen, is in development across several clinical settings, including potential applications in oncology and rare diseases. Atossa has received FDA Orphan Drug Designation for (Z)-endoxifen for Duchenne muscular dystrophy and Rare Pediatric Disease designations for Duchenne muscular dystrophy and McCune-Albright syndrome. (Z)-endoxifen is not approved for any indication. More information is available at atossatherapeutics.com.
Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of applicable securities laws, including but not limited to, the Company's potential eligibility for, award of a Rare Pediatric Disease priority review voucher, the potential value and monetization of a qualifying voucher, the operation of the CVRs; the development, regulatory prospects and potential approval of Atossa's product candidates; and the possibility, amount and timing of any CVR payment. Words such as "expect," "potential," "continue," "may," "will," "should," "could," "would," "seek," "intend," "plan," "estimate," "anticipate," "believe," "design," "predict," "future," or other similar expressions or statements regarding intent, belief or current expectations, are forward-looking statements.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes to differ materially from those projected or anticipated, including, without limitation, risks and uncertainties associated with: the timing or likelihood of regulatory filings and approvals; the outcome or timing of necessary regulatory approvals; FDA approval of a qualifying product candidate and the award of a voucher; changes to or expiration of the applicable voucher program; the risk that any voucher's value, permitted deductions, number of outstanding CVRs and ability or timing to make a payment may differ materially from current expectations; and other risks and uncertainties detailed from time to time in Atossa's filings with the SEC, including, without limitation, its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Any CVR payment is subject to the CVR agreement, including its payment cap and provisions concerning legally permitted distributions and solvency.
The market value of a priority review voucher is variable and subject to a number of factors beyond our control and reported past priority review voucher sale amounts are not necessarily indicative of priority review voucher sale amounts in the future.
Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/atossa-therapeutics-common-stock-to-begin-trading-with-stapled-contingent-value-rights-after-close-of-business-today-302912344.html
SOURCE Atossa Therapeutics Inc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much could Atossa CVR holders receive?
CVR holders are entitled collectively to 25% of net proceeds from the sale or deemed monetization of Atossa’s first qualifying priority review voucher, with total payments capped at $50 million. The voucher must be awarded on or before December 31, 2036, unless the board extends that date. A payment is not assured.
How is Atossa’s voucher valued if it is used internally or held during a change of control?
An independent financial advisor determines fair market value for deemed monetization. This applies if Atossa uses a qualifying voucher for its own application or a change of control occurs while Atossa holds an unsold qualifying voucher.